Story perspectives

Lilly and NVIDIA Join Forces for Revolutionary Drug Discovery Supercomputer

10/28/2025

Summary

Story summary

Eli Lilly and Company and NVIDIA Corporation will build the pharmaceutical industry's most powerful supercomputer to accelerate drug discovery.
The system will launch in January 2026, use over 1,000 NVIDIA GPUs, and run on renewable energy.
It will support an AI factory for training models on extensive experimental data to identify drug candidates faster.
Lilly's TuneLab platform will give biotech companies access to proprietary AI models while preserving data privacy.

History

Historical Context

IBM's Watson's victory in Jeopardy! in 2011 marked a pivotal moment in AI, spurring significant investments in the technology. Companies like Eli Lilly and NVIDIA are now collaborating to create a supercomputer with over 1,000 GPUs, aiming to transform drug discovery. This initiative reflects a broader trend in leveraging AI for pharmaceutical advancements, promising enhanced efficiency in drug development.

1 of 2

Story summary

Eli Lilly and Company and NVIDIA Corporation will build the pharmaceutical industry's most powerful supercomputer to accelerate drug discovery.
The system will launch in January 2026, use over 1,000 NVIDIA GPUs, and run on renewable energy.
It will support an AI factory for training models on extensive experimental data to identify drug candidates faster.
Lilly's TuneLab platform will give biotech companies access to proprietary AI models while preserving data privacy.

1 / 2